2006
DOI: 10.1016/j.tips.2006.06.004
|View full text |Cite
|
Sign up to set email alerts
|

Nucleoside transporters: from scavengers to novel therapeutic targets

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

3
242
0
4

Year Published

2008
2008
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 260 publications
(249 citation statements)
references
References 67 publications
3
242
0
4
Order By: Relevance
“…Both ENTs and CNTs are expressed in highly metabolically active tissues, including the brain. However, they differ in selectivity, kinetics, regulation and subcellular distribution (King et al, 2006).…”
Section: Adenosine Transportmentioning
confidence: 99%
See 1 more Smart Citation
“…Both ENTs and CNTs are expressed in highly metabolically active tissues, including the brain. However, they differ in selectivity, kinetics, regulation and subcellular distribution (King et al, 2006).…”
Section: Adenosine Transportmentioning
confidence: 99%
“…The CNT family demonstrates a more distinct selectivity in nucleoside transporting than the ENT family. Most CNTs show a pyrimidine preference with similar affinity to adenosine molecules, yet the rate of adenosine transport by CNT1 is much lower than the rate of pyrimidine transport and CNT1 displays a much lower turnover number of molecules per second than ENT1 (King et al, 2006). Interestingly, acute ethanol treatment in neuronal cells is known to increase extracellular adenosine, whereas chronic exposure no longer increases adenosine.…”
Section: Adenosine Transportmentioning
confidence: 99%
“…The very short half-life of adenosine in blood and other fluids, typically measured in seconds, limits the activity of adenosine as an extracellular signal and maintenance of adenosine levels in extracellular fluids is the result of an equilibrium between production and consumption [23]. A basal level of extracellular adenosine is maintained between 30 and 200 nM [24,25]. Extracellular adenosine is cytoprotective, increases oxygen supply, angiogenesis, and protects against ischemic damage [26].…”
Section: Adenosine Signalingmentioning
confidence: 99%
“…Consequently, the energy status of hypoxic cells is precarious and leads to high intracellular levels of adenosine as ATP is broken down by the sequential actions of adenosine kinase and cytosolic 5 0 -nucleotidase (Sala-Newby et al, 1999). Adenosine can enter the tumor microenvironment through equilibrative nucleoside transporters (King et al, 2006) or be formed by extracellular ecto-phosphopyrases (such as CD39) and ecto-5 0 -nucleotidases (such as CD73) when necrotic cells spill their intracellular contents (Lasley et al, 1999). High levels of adenosine in the tumor microenvironment (Blay et al, 1997) may be a major obstacle to the development of TLR tolerization in cancer cells as adenosine is an especially strong negative regulator of TLR signaling, prevents TNF-a synthesis after initial TLR stimulation and accounts for poor responses of neonates to endotoxin in vivo (Levy et al, 2006).…”
Section: Adenosinementioning
confidence: 99%
“…Adenosine can be taken up through concentrative, as well as equilibrative, transporters (King et al, 2006) and enter the cytoplasm where it has a number of possible fates that may profoundly affect subsequent responses to TLR agonists. It can be degraded to inosine via adenosine deaminase, and subsequently to uric acid, without much impact on TLR signaling.…”
Section: Adenosinementioning
confidence: 99%